MARKET

BBI

BBI

Brickell Biotech Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7200
+0.0100
+1.41%
After Hours: 0.7200 0 0.00% 18:38 09/21 EDT
OPEN
0.7100
PREV CLOSE
0.7100
HIGH
0.7447
LOW
0.7080
VOLUME
375.50K
TURNOVER
--
52 WEEK HIGH
1.700
52 WEEK LOW
0.4660
MARKET CAP
61.86M
P/E (TTM)
-0.9430
1D
5D
1M
3M
1Y
5Y
Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and its Role in Autoimmunity
Brickell Biotech, Inc. ("Brickell") (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other deb...
GlobeNewswire · 4d ago
Brickell Biotech to Participate at Upcoming September Conferences
Brickell Biotech, Inc. ("Brickell") (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other deb...
GlobeNewswire · 09/08 12:30
Brickell buys drug prospect, adds new CMO
Brickell Biotech Inc. (Nasdaq: BBI) has acquired a clinical-stage drug candidate and added a chief medical officer to its stable of C-suite senior executives.
University Wire · 09/02 03:13
Brickell Biotech Acquires Rights To Candidate For Autoimmune Diseases
Benzinga · 09/01 16:25
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31)
Benzinga · 09/01 11:32
BRIEF-Brickell Biotech Acquires Exclusive Rights To Phase 1-Ready Dyrk1a Inhibitor Program And Novel Platform Targeting Autoimmune And Inflammatory Diseases
reuters.com · 09/01 11:29
Brickell Biotech Expands Leadership Team, Appointing Dr. Monica Luchi as Chief Medical Officer
Dr. Luchi brings over 20 years of immunotherapeutic and drug development experience and will lead Brickell’s clinical development strategy and medical affairs functionsBOULDER, Colo., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or...
GlobeNewswire · 09/01 11:05
Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases
Expect to initiate Phase 1 clinical study of lead DYRK1A inhibitor program, BBI-02, a potential first-in-class oral treatment for autoimmune and inflammatory diseases, in 2022 Acquisition includes rights to platform of
Benzinga · 09/01 11:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BBI. Analyze the recent business situations of Brickell Biotech Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BBI stock price target is 5.50 with a high estimate of 6.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 54
Institutional Holdings: 8.03M
% Owned: 9.34%
Shares Outstanding: 85.92M
TypeInstitutionsShares
Increased
8
1.93M
New
7
192.92K
Decreased
6
61.45K
Sold Out
5
169.36K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.45%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/Co-Founder/Director
Reginald Hardy
Chief Executive Officer/Director
Robert Brown
Co-Founder/Chief Operating Officer/Secretary
Andrew Sklawer
Chief Financial Officer
Albert Marchio
Chief Accounting Officer/Controller
Jose Breton
Chief Compliance Officer/General Counsel/Secretary
David McAvoy
Other
Deepak Chadha
Other
Adam Levy
Director
Gary Lyons
Director
Vijay Samant
Director
Dennison Veru
No Data
About BBI
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company. The Company focuses on the development of therapeutics for the treatment of skin diseases. The Company's Phase III clinical-stage investigational product candidate, sofpironium bromide, is a chemical entity that belongs to a class of medications called anticholinergics is for the treatment of primary axillary (underarm) hyperhidrosis. The Company is also conducting early research programs targeting various skin diseases.

Webull offers kinds of Brickell Biotech Inc stock information, including NASDAQ:BBI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BBI stock methods without spending real money on the virtual paper trading platform.